2084-LB: Real-World Effectiveness of Tirzepatide among People with Obesity or Overweight without Type 2 Diabetes (T2D)

• Published in: Diabetes (New York, N.Y.) Vol. 73; p. 1
• Main Authors: Hankosky, Emily R, Desai, Karishma, Chinthammit, Chanadda, Grabner, Michael, Stockbower, Grace, He, Xuanyao, Mojdami, Donna, Wenziger, Cachet, Gibble, Theresa Hunter
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2024
• Subjects: Antidiabetics; Body weight; Body weight loss; Comorbidity; Diabetes; Diabetes mellitus (non-insulin dependent); Dyslipidemia; Obesity; Overweight; Patients; Weight control
• DOI: 10.2337/db24-2084-LB
• ISSN: 0012-1797

Introduction & Objective: Tirzepatide is a once weekly GIP and GLP-1 receptor agonist approved in the US for treatment of T2D (May 2022) and obesity (Nov 2023). We assessed real-world patient characteristics and effectiveness in people with obesity or overweight without T2D. Methods: This retrospective study was conducted using the Healthcare Integrated Research Database (HIRD®). Date of first tirzepatide claim (index date; NDCs for Mounjaro®) was between May 13, 2022 - June 30, 2023. Because tirzepatide was only approved for the treatment of T2D during the index period, any use of tirzepatide by individuals without T2D during this time was off-label and solely at the discretion of their prescribing physician. Demographic and clinical characteristics were assessed among adults (≥18 years) without T2D diagnostic codes or treatment, but eligible for anti-obesity medication (AOM; BMI ≥30 kg/m2; or BMI ≥27 kg/m2 with ≥1 obesity-related comorbidity; ORC). Weight changes were assessed among individuals with ≥6 months tirzepatide persistence (<60-day gap) and weight data at baseline and 6-months post-index. Results: Among the 699 AOM-eligible adults without TD2 diagnostic codes who filled a prescription for tirzepatide, most were female (77.1%), White (81.1%), mean age 47.2 years, mean BMI 38.3 kg/m2, mean weight 109.3 kg (241.0 lbs), and of those with a 6th prescription fill (n=405), 44.4% was for ≥10 mg. At least one ORC was reported in 86.4% of patients. Hypertension (44.5%), dyslipidemia (43.6%), and anxiety (35.8%) were the most common ORCs. Of the 68.8% (n=481) who were persistent for ≥6 months, weight data were available at baseline and 6-months post-index for n=199; 88.4% had ≥5%, 68.8% had ≥10%, and 36.7% had ≥15% weight reduction at 6-months post-index. The average weight reduction was 12.7% (14.1 kg [31.1 lbs]). Conclusion: At 6-months, most users of tirzepatide without T2D diagnostic codes were persistent and lost ≥10% body weight with an average body weight loss of 12.7%.